Scandinavian ChemoTech's Medical Director presents clinical strategy
On Friday, January 27, 2023, Scandinavian ChemoTech will publish a pre-recorded interview with the company's Medical Director Dr. Suhail Mufti. The presentation aims to provide an update on Scandinavian ChemoTech's clinical strategy.
The interview will be published on ChemoTech's website and distributed via the company's YouTube channel.
https://www.youtube.com/@scandinavianchemotechabpub4074
For shareholders and other interested parties who wish to submit questions to Dr. Mufti. This can be done via email at ir@chemotech.se, no later than Wednesday, January 25.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
